GLyPharma Therapeutic
Montréal
About GLyPharma Therapeutic
GLyPharma was created in Montréal in August 2012 for the purpose of a strategic partnership between Ferring Pharmaceuticals, a European pharmaceutical company specialized in the discovery and development of active peptides, FONDS de solidarité FTQ and CTI Life Sciences Fund. The compound, FE 203799, is a long-acting GLP-2 receptor agonist, with intestine-trophic and intestine-protective activity. GLyPharma is granted by Ferring an exclusive worldwide license for development and commercialization of this compound as first-in-class indication in supportive care in oncology for protecting from chemotherapy-induced intestinal mucositis.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $12.2M
- Funding stage: M&A
- Last round: Series A (Sep 2012)
- Website: glypharma.com
- Phone: (514)876-4220
Industries & Categories
Biotechnology, Health Care, Medical, Oncology, Therapeutics
Canonical: https://fsome.com/organization/glypharma-therapeutic-1309562 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.